Services

The LCDT1 is a blood test for early detection of lung cancer. The test is indicated in patients with long history of smoking and at a high risk of developing lung cancer.

For questions on medical coverage, please consult your insurance provider. In case the test is not covered by your insurance provider, and you cannot afford it, you maybe eligible to participate in our ongoing clinical trial.

If you are a clinician and would like to make the test available to your patients, please contact us.

For researchers, Lung Cancer Proteomics also offers licensing of our patents.

LCDT1

Blood test for detecting early stage Non-Small Cell Lung Cancer.

Licensing

For researchers and academics interested in licensing our patent(s).

Clinical Trial

For patients interested in participating in our ongoing clinical trial.

Clinic

For clinics/hospitals who would like to provide this test to their patients.

PRECAUTION: The LCDT1 is an adjunctive device and should not be used without an independent clinical/radiological evaluation. The LCDT1 is not intended to be a screening test or to determine whether a patient should proceed with surgery. Incorrect use of the LCDT1 Test carries the risk of unnecessary follow-up procedures and/or delayed diagnosis.

Insert Content Template or Symbol
Insert Video

Lung Cancer Proteomics, LLC
Headquarters
105 Washington Street
Michigan City, IN 46360

Bay Area Laboratory
780 Montague Expressway
Building 7, Suite 703
San Jose, CA 95131

LinkedIn - Lung Cancer Proteomics
Twitter - Lung Cancer Proteomics
Facebook - Lung Cancer Proteomics

© 2019 Lung Cancer Proteomics. All rights reserved.